American Society of Hematology

Fig. 7.

$Fig. 7. Western blot analysis of pIL-1β in lysates of DH-VD3–pretreated THP-1 cells that were treated with various inhibitors before LPS stimulation. DH-VD3–pretreated THP-1 cells were stimulated with 100 ng/mL of S minnesota Re 595 LPS in the absence or presence of various inhibitors, as indicated. Total lysate (30 μg protein/lane) was fractionated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted. The 33-kD IL-1β precursor protein reacts with an anti–IL-1β antibody as described in the Materials and Methods. Concentrations of the inhibitors used were 5 ng/mL actinomycin D, 5 μg/mL cycloheximide, and 20 μmol/L for YVAD-CHO and YVAD-CMK.$

Western blot analysis of pIL-1β in lysates of DH-VD₃–pretreated THP-1 cells that were treated with various inhibitors before LPS stimulation. DH-VD₃–pretreated THP-1 cells were stimulated with 100 ng/mL of S minnesota Re 595 LPS in the absence or presence of various inhibitors, as indicated. Total lysate (30 μg protein/lane) was fractionated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted. The 33-kD IL-1β precursor protein reacts with an anti–IL-1β antibody as described in the Materials and Methods. Concentrations of the inhibitors used were 5 ng/mL actinomycin D, 5 μg/mL cycloheximide, and 20 μmol/L for YVAD-CHO and YVAD-CMK.

This Feature Is Available To Subscribers Only